What does CUSIP 67080M103 represent in this 13F holders report?

CUSIP 67080M103 is the security identifier for NRIX - Nurix Therapeutics, Inc. - COMMON STOCK used to aggregate holder disclosures.

How many institutions held NRIX - Nurix Therapeutics, Inc. - COMMON STOCK in Q2 2022?

100 institutional investors reported NRIX - Nurix Therapeutics, Inc. - COMMON STOCK for Q2 2022. Use the holders table for investor-level position and value details.

Nurix Therapeutics, Inc. - COMMON STOCK (NRIX)

CUSIP: 67080M103

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / COMMON STOCK
Shares outstanding: 102,616,132
Total 13F shares: 44,940,935
Share change: +4,599,230
Total reported value: $567,552,048
Price per share: $12.67
Number of holders: 100
Value change: +$55,435,115
Number of buys: 54
Number of sells: 48

Quarterly Holders Quick Answers

What is CUSIP 67080M103?
CUSIP 67080M103 identifies NRIX - Nurix Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 67080M103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of NRIX - Nurix Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	4.7%	4,806,289	$67,336,000	—	31 Mar 2022	13F
Redmile Group, LLC	13F	Company	2.9%	3,018,784	$42,293,000	—	31 Mar 2022	13F
BlackRock Finance, Inc.	13F	Company	2.5%	2,524,643	$35,370,000	—	31 Mar 2022	13F
Third Rock Ventures III, L.P.	3/4/5	10%+ Owner	— class O/S missing	3,509,348	$35,104,359	—	06 May 2021	3/4/5
BAKER BROS. ADVISORS LP	13F	Company	2.4%	2,454,082	$34,382,000	—	31 Mar 2022	13F
STATE STREET CORP	13F	Company	2.2%	2,302,544	$32,259,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	2%	2,028,063	$28,413,000	—	31 Mar 2022	13F
TRV GP III, LLC	13F	Company	1.9%	1,922,549	$26,935,000	—	31 Mar 2022	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	1.8%	1,870,000	$26,199,000	—	31 Mar 2022	13F
WASATCH ADVISORS LP	13F	Company	1.5%	1,546,689	$21,669,000	—	31 Mar 2022	13F
PICTET ASSET MANAGEMENT SA	13F	Company	1.4%	1,439,282	$20,164,000	—	31 Mar 2022	13F
Bain Capital Life Sciences Investors, LLC	13F	Company	1.3%	1,284,313	$17,993,000	—	31 Mar 2022	13F
Boxer Capital, LLC	13F	Company	1.2%	1,224,892	$17,161,000	—	31 Mar 2022	13F
FMR LLC	13F	Company	1.1%	1,122,023	$15,720,000	—	31 Mar 2022	13F
Foresite Capital Management IV, LLC	13F	Company	1%	1,030,798	$14,441,000	—	31 Mar 2022	13F
COLUMN GROUP L P	3/4/5	10%+ Owner	— class O/S missing	1,442,739	$14,431,862	—	07 May 2021	3/4/5
Soleus Capital Management, L.P.	13F	Company	0.99%	1,011,638	$14,173,000	—	31 Mar 2022	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.82%	842,373	$11,802,000	—	31 Mar 2022	13F
S.c.a. Candriam	13F	Individual	0.75%	765,076	$10,718,000	—	31 Mar 2022	13F
MORGAN STANLEY	13F	Company	0.66%	680,859	$9,538,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.64%	652,494	$9,141,000	—	31 Mar 2022	13F
DAFNA Capital Management LLC	13F	Company	0.53%	543,344	$7,612,000	—	31 Mar 2022	13F
ARK Investment Management LLC	13F	Company	0.38%	391,991	$5,492,000	—	31 Mar 2022	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.36%	366,232	$5,131,000	—	31 Mar 2022	13F
Ponoi II Management, LLC	13F	Company	0.32%	327,123	$4,583,000	—	31 Mar 2022	13F
Ponoi Management, LLC	13F	Company	0.32%	327,122	$4,583,000	—	31 Mar 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.31%	315,666	$4,423,000	—	31 Mar 2022	13F
HARVARD MANAGEMENT CO INC	13F	Company	0.31%	314,762	$4,410,000	—	31 Mar 2022	13F
BESSEMER GROUP INC	13F	Company	0.3%	305,013	$4,274,000	—	31 Mar 2022	13F
NORTHERN TRUST CORP	13F	Company	0.3%	304,537	$4,266,000	—	31 Mar 2022	13F
NOMURA HOLDINGS INC	13F	Company	0.3%	305,340	$4,265,000	—	31 Mar 2022	13F
WestHill Financial Advisors, Inc.	13F	Company	0.28%	283,333	$3,969,000	—	31 Mar 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.26%	270,055	$3,784,000	—	31 Mar 2022	13F
EcoR1 Capital, LLC	13F	Company	0.25%	254,473	$3,565,000	—	31 Mar 2022	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.25%	253,272	$3,548,340	—	31 Mar 2022	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.23%	237,525	$3,328,000	—	31 Mar 2022	13F
Woodline Partners LP	13F	Company	0.21%	219,281	$3,072,000	—	31 Mar 2022	13F
CITADEL ADVISORS LLC	13F	Company	0.21%	211,783	$2,967,000	—	31 Mar 2022	13F
Of The University Of California Regents	13F	Individual	0.2%	204,123	$2,860,000	—	31 Mar 2022	13F
UBS Group AG	13F	Company	0.14%	148,684	$2,083,000	—	31 Mar 2022	13F
Rafferty Asset Management, LLC	13F	Company	0.14%	146,280	$2,049,000	—	31 Mar 2022	13F
Alyeska Investment Group, L.P.	13F	Company	0.12%	120,750	$1,692,000	—	31 Mar 2022	13F
JPMORGAN CHASE & CO	13F	Company	0.12%	120,516	$1,688,000	—	31 Mar 2022	13F
Bank of New York Mellon Corp	13F	Company	0.1%	104,122	$1,458,000	—	31 Mar 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.1%	105,391	$1,437,000	—	31 Mar 2022	13F
Jasper Ridge Partners, L.P.	13F	Company	0.1%	98,687	$1,383,000	—	31 Mar 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.09%	91,335	$1,280,000	—	31 Mar 2022	13F
Pierre Beaurang	3/4/5	Chief Business Officer	— mixed-class rows	127,558 mixed-class rows	$1,210,335	—	10 Aug 2021	3/4/5
Ensign Peak Advisors, Inc	13F	Company	0.08%	84,797	$1,188,000	—	31 Mar 2022	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.07%	76,200	$1,068,000	—	31 Mar 2022	13F

Institutional Holders of Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) as of Q2 2022

As of 30 Jun 2022, Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) was held by 100 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 44,940,935 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, BlackRock Inc., Redmile Group, LLC, Deep Track Capital, LP, WASATCH ADVISORS INC, STATE STREET CORP, VANGUARD GROUP INC, TRV GP III, LLC, and Bain Capital Life Sciences Investors, LLC. This page lists 100 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

111

Q2 2022 holders

100

Holder diff

-11

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.